Successfully reported this slideshow.
Your SlideShare is downloading. ×

corticosteroids bds ppt.pptx

Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Ad
Upcoming SlideShare
ACTH and Corticosteroids.ppt
ACTH and Corticosteroids.ppt
Loading in …3
×

Check these out next

1 of 36 Ad

More Related Content

Similar to corticosteroids bds ppt.pptx (20)

Recently uploaded (20)

Advertisement

corticosteroids bds ppt.pptx

  1. 1. Corticosteroids Dr.Deepak Daniel
  2. 2. Outline for today’s session Introduction Actions of corticosteroids Pharmacokinetics Distinctive features Adverse effects Uses Contraindications Dental implications
  3. 3. Introduction ‘Corticosteroid’ or ‘corticoid’ includes natural gluco- and mineralocorticoids and their synthetic analogues. 21 carbon compounds having a cyclopentanoperhydro-phenanthrene (steroid) nucleus. Synthesized in the adrenal cortical cells from cholesterol. Adrenal steroidogenesis takes place under the influence of ACTH which is under negative feed back regulation by circulating cortisol level . The normal rate of secretion of the two principal corticoids in man is— Hydrocortisone (cortisol) — 1 0 - 2 0 m g d a i l y (nearly half of this in the few morning hours). Aldosterone — 0.125 mg daily
  4. 4. Actions of corticosteroids Glucocorticoid action Mineralocorticoid action
  5. 5. Mineralocorticoid Action Aldosterone is the natural mineralocorticoid. Increased Na+ reabsorption DCT  associated with increased K+ and H+ excretion is the principal mineralocorticoid action. Excess of this action leads to Na+ and water retention, edema, progressive rise in BP, hypokalaemia and alkalosis. Mineralocorticoid deficiency results in progressive Na+ loss → dilutional hyponatraemia → cellular hydration → decreased blood volume. Hyperkalaemia and acidosis accompany.
  6. 6. Glucocorticoid actions 1.Carbohydrate and protein metabolism Glucocorticoids promote glycogen deposition in liver by inducing hepatic glycogen synthetase and promoting gluconeogenesis. They inhibit glucose utilization by peripheral tissues. This along with increased glucose release from liver results in hyperglycaemia, resistance to insulin and a diabetes-like state.
  7. 7. • Glucocorticoids also promote protein breakdown and amino acid mobilization from peripheral tissues which is responsible for side effects like muscle wasting, lympholysis, loss of osteoid from bone and thinning of skin. • The amino acids so mobilized funnel into liver and are used up in gluconeogenesis, excess urea is produced resulting in negative nitrogen balance. • Glucocorticoids are thus catabolic. • Their function appears to be oriented to maintaining blood glucose levels during starvation— so that brain continues to get its nutrient. • Corticosteroids increase uric acid excretion. Protein metabo lism
  8. 8. 2. Fat metabolism • Corticoids promote lipolysis. • Redistribution of body fat occurs. • Subcutaneous tissue over extremities loses fat which is deposited over face, neck and shoulder. • characteristic ‘moon face’, ‘fish mouth’, ‘buffalo hump’. 3. Calcium metabolism • Cortisol inhibits intestinal absorption and enhances renal excretion of Ca2+. • Loss of osteoid indirectly contributes to loss of Ca2+ from bone producing osteoporosis. • Spongy bones (vertebrae, pelvis, ribs, etc.) are more sensitive.
  9. 9. • Glucocorticoids, but not aldosterone, maintain g.f.r. and help excreting excess water load. 4. Water excretion • Glucocorticoids restrict capillary permeability. • Maintain tone of arterioles and myocardial contractility. • Permissive role in the development of hypertension. 5. CVS
  10. 10. • Weakness occurs in both hypo- and hypercorticism, but the causes are different. • Hypocorticism: diminished work capacity and weakness are primarily due to hypodynamic circulation. • Hypercorticism: excess mineralocorticoid action → hypokalaemia → weakness; Excess glucocorticoid action → muscle wasting and myopathy → weakness. 6. Skeletal muscles • Mild euphoria is quite common with supraphysiological doses of glucocorticoids. • This sometimes progresses to cause insomnia, anxiety or depression as side effect of corticosteroid therapy. 7. CNS
  11. 11. • Secretion of gastric acid and pepsin is increased—may aggravate peptic ulcer. 8. Stomach • Glucocorticoids enhance the rate of destruction of lymphoid cells (T cells are more sensitive than B cells). • A marked lytic response is shown by malignant lymphatic cells. • Corticosteroids are palliative in lymphomas. 9. Lymphoid tissue
  12. 12. 10. Inflammatory responses This is the basis of most of their clinical uses. The action is direct and can be restricted to a site by local application. The cardinal signs of inflammation—redness, heat, swelling and pain are suppressed. Most important overall mechanism appears to be limitation of recruitment of inflammatory cells at the local site. Production of PGs and several other mediators of inflammation like LTs, PAF, TNFα and cytokines is interfered. Glucocorticoids induce formation of anti-inflammatory protein called annexins. Corticoids are only palliative, do not remove the cause of inflammation. They favour spread of infections because capacity of defensive cells to kill microorganisms is impaired. They also interfere with healing and scar formation: peptic ulcer may perforate asymptomatically
  13. 13. 11. Immunological and allergic responses Glucocorticoids impair immunological competence. Suppress all types of hypersensitization and allergic phenomena. Suppression of recruitment of leukocytes at the site of contact with the antigen, and of inflammatory response to immunological injury. Greater suppression of cell mediated immunity (CMI) in which T cells are primarily involved, e.g. delayed hypersensitivity and graft rejection. This is the basis of use in autoimmune diseases and organ transplantation.
  14. 14. Mechanism of action at cellular level Corticosteroids penetrate cells and bind to a high affinity cytoplasmic receptor protein → a structural change occurs in the steroid-receptor complex that allows its migration into the nucleus and binding to the glucocorticoid response elements (GRE) on the chromatin → transcription of specific m-RNA → regulation of protein synthesis. This process takes at least 30-60 min. Therefore, effects of corticosteroid are not immediate, and once the appropriate proteins are synthesized—effects persist much longer than the steroid itself. In many tissues, the overall effect is catabolic, i.e. inhibition of protein synthesis. This may be a consequence of steroid directed synthesis of an inhibitory protein. The glucocorticoid receptor (GR) is very widely distributed (in practically all cells of the body). Therefore, effects of corticosteroids are widespread.
  15. 15. Pharmacokinetics All natural and synthetic corticoids are absorbed by the oral route. Hydrocortisone undergoes high first pass metabolism. Therefore, it has low oral: parenteral activity ratio. Oral bioavailability of synthetic corticoids is high. Hydrocortisone is 90% bound to plasma protein, mostly to a specific cortisol-binding globulin (CBG or transcortin) as well as to albumin. The steroids are metabolized primarily by hepatic microsomal enzymes. The metabolites are excreted in urine. The plasma t½ of hydrocortisone is 1.5 hours. However, biological effect t½ is longer because of action through intracellular receptors and regulation of protein synthesis—effects that persist long after the steroid is removed from plasma. The synthetic corticosteroids are more resistant to metabolism and are longer acting. Phenobarbitone and phenytoin induce metabolism of hydrocortisone, prednisolone and dexamethasone, etc. to decrease their therapeutic effect
  16. 16. Distinctive features • In addition to primary glucocorticoid, it has significant mineralocorticoid activity with rapid and short lasting action. 1. Hydrocortisone (cortisol) • 4 times more potent than hydrocortisone. • More selective glucocorticoid, but fluid retention does occur with high doses. • Intermediate duration of action • Less pituitary-adrenal suppression when a single morning dose or alternate day treatment is given. • It is used for allergic, inflammatory, autoimmune diseases and in malignancies. 2. Prednisolone
  17. 17. • Slightly more potent and more selective than prednisolone. • Pulse therapy with high dose methylprednisolone (1 g infused i.v. every 6–8 weeks) has been tried in nonresponsive active rheumatoid arthritis, renal transplant, pemphigus, etc. 3. Methylprednisol one • Slightly more potent than prednisolone but highly selective glucocorticoid 4. Triamcinolone
  18. 18. •Very potent and highly selective glucocorticoid. •Long acting, causes marked pituitary-adrenal suppression, but fluid retention and hypertension are not a problem. •It is used for inflammatory and allergic conditions, shock, cerebral edema, etc. 5. Dexamethasone • Similar to dexamethasone. • Dexamethasone or betamethasone are preferred in cerebral edema and other states in which fluid retention must be avoided. 6. Betamethasone •It is a highly selective glucocorticoid, dose-to-dose slightly less potent than prednisolone, but lacks mineralocorticoid activity. •It is claimed to produce fewer adverse effects and less growth retardation in children. 7. Deflazacort
  19. 19. Adverse effects • Sodium and water retention, edema, hypokalaemic alkalosis and a progressive rise in BP is a consequence of mineralocorticoid action. • This is infrequent now, because more selective glucocorticoids are generally used. • Gradual rise in BP occurs due to excess glucocorticoid action as well. Minera locorti coid
  20. 20. B. Glucocorticoid 1.Cushing’s habitus characteristic appearance with rounded face, narrow mouth, supraclavicular hump, obesity of trunk with relatively thin limbs. 2.Fragile skin, purple striae—easy bruising, telengiectasis, hirsutism. Cutaneous atrophy occurs with topical application of the steroid as well. 3.Hyperglycaemia, precipitation of diabetes. 4.Muscular weakness, especially of proximal limb muscles; myopathy occurs occasionally. 5.Susceptibility to infection; opportunistic infections with low-grade pathogens (Candida, etc.).
  21. 21. 6. Delayed healing of wounds. 7. Peptic ulceration. 8. Osteoporosis Specially involving vertebrae and other flat spongy bones. 9. Growth retardation in children occurs even with small doses if given for long periods. 10. Foetal abnormalities cleft palate and other defects are produced in animals, but have not been encountered in pregnant women. 11. Psychiatric disturbances.
  22. 22. 12. Suppression of hypothalamo-pituitary adrenal (HPA) axis occurs depending both on dose and duration of therapy. In time, adrenal cortex atrophies and stoppage of exogenous steroid precipitates a withdrawal syndrome producing malaise, anorexia, nausea, postural hypotension, weakness, etc. and reactivation of the disease. Subjected to stress, these patients may go into acute adrenal insufficiency. Any patient who has received > 20– 25 mg/ day hydrocortisone or equivalent such as ≥ 5 mg prednisolone/day for longer than 2–3 weeks should be put on a scheme of gradual withdrawal. Such patients may need protection with steroids if a stressful situation develops up to one year after withdrawal. If a patient on corticosteroid therapy develops an infection—the steroid should not be discontinued despite its propensity to weaken host defence. Rather, the dose may have to be increased to meet the stress of the infection
  23. 23. • Use shorter acting steroids (hydrocortisone, prednisolone) at the lowest possible dose. • Use steroids for the shortest period of time possible • Give the entire daily dose at one time in the morning. • Switch to alternate-day therapy if the condition does not deteriorate on the ‘off’ day. • If appropriate, use local (dermal, inhaled, ocular, nasal, buccal, rectal, intrasynovial) preparations Measures that minimise HPA axis
  24. 24. Uses Systemic as well as topical corticosteroids have one of the widest spectrum of medical uses for their anti-inflammatory and immunosuppressive properties. They are powerful drugs. Potential to cause dramatic improvement in many severe diseases, but can produce equally serious adverse effects.
  25. 25. 1.Collagen and autoimmune diseases, e.g. systemic lupus erythematosus, polyarteritis nodosa, nephrotic syndrome, glomerulonephritis, rheumatoid arthritis, rheumatic fever 2. Severe allergic reactions: anaphylaxis, angioneurotic edema, urticaria, serum sickness. 3. Bronchial asthma: majority of cases are treated with inhaled steroids. Other lung conditions  pulmonary edema, aspiration pneumonia, allergic rhinitis. Dexamethasone/betamethasone given to pregnant women before premature delivery, prevent respiratory distress syndrome in the neonate. 4. Eye diseases: allergic conjunctivitis, iridocyclitis, keratitis, uveitis, retinitis, optic neuritis, etc.
  26. 26. 5. Skin diseases: mostly topical use in dermatitis; systemic steroids are needed in pemphigus vulgaris, exfoliative dermatitis, Stevens-Johnson syndrome and other serious disorders 6. Inflammatory bowel disease: ulcerative colitis, Crohn’s disease. 7. Infective diseases: only in serious/life threatening infective diseases under effective antimicrobial cover, e.g. in bacterial/tubercular meningitis, miliary tuberculosis, severe lepra reaction, etc
  27. 27. 8. Neurological conditions: like cerebral edema due to tubercular meningitis/ cerebral tumours, Bells’ palsy, neurocysticercosis. 9. Malignancies: acute lymphatic leukaemia, Hodgkin’s disease, lymphomas, etc. 10. Nausea and vomiting: Dexamethasone injected i.v. is used to augment the antiemetic effect of ondansetron against cancer chemotherapy induced vomiting. 11. Renal and other organ transplantation, skin allograft. 12. Substitution therapy in acute and chronic adrenal insufficiency and congenital adrenal hyperplasia.
  28. 28. Contraindications 1.Peptic ulcer 2. Diabetes mellitus 3. Hypertension 4. Viral and fungal infections 5. Tuberculosis and other infections 6. Osteoporosis 7. Herpes simplex keratitis 8. Psychosis 9. Epilepsy 10. CHF 11. Renal failure.
  29. 29. Implications In Dentistry Application of corticosteroids in dental conditions is rather limited. Recurrent oral ulceration may be treated with topical steroids, but maintaining long enough contact between the steroid and the oral lesion is often difficult. Severe oral lesions like pemphigus, erosive lichen planus, etc. need to be treated with systemic corticosteroids. Pain from exposed dental pulp is occasionally treated with locally applied steroids. Intraarticular hydrocortisone may be injected in the temporomandibular joint to relieve refractory pain and stiffness. Only rarely a corticosteroid is needed to suppress pain and swelling due to dental surgery, (e.g. impacted third molar extraction), for which NSAIDs are the first line drugs.
  30. 30. In the case of patients who are/have been in recent past on long-term corticosteroid therapy, consideration has to be given to the need for supplementary prophylactic corticoid to cover a dental procedure. In general, simple extractions and other mildly traumatic surgeries do not warrant additional steroid dose. For traumatic procedures and those to be performed under general anaesthesia, supplementary steroids may be needed, particularly if the dose and duration of steroid therapy are such as to have caused significant adrenal suppression, or the patient is excessively anxious. Monitoring of BP of such patients during surgery is required. In case BP falls, hydrocortisone should be injected i.v. immediately.
  31. 31. Common oro-dental conditions Aphthous ulcer Pulp capping Pulp pulpotomy Post extraction of tooth Temporomandibular arthritis Desquamative gingivitis Oral lichen planus Oral Pemphigus Oral submucosal fibrosis
  32. 32. Summarize Actions of corticosteroids? Mineralocorticoid action? Glucocorticoid action?Short and long acting ? Adverse effects ? Uses? Contraindications? Dental implications?

Editor's Notes

  • . Conventionally, the term ‘corticosteroid’ or ‘corticoid’ includes natural gluco- and mineralocorticoids and their synthetic analogues. The corticoids (both gluco and mineralo) are 21 carbon compounds having a cyclopentanoperhydro-phenanthrene (steroid) nucleus. They are synthesized in the adrenal cortical cells from cholesterol. Adrenal steroidogenesis takes place under the influence of ACTH (see p. 232) which is under negative feed back regulation by circulating cortisol level (Fig. 14.5). The normal rate of secretion of the two principal corticoids in man is— Hydrocortisone (cortisol) — 1 0 - 2 0 m g d a i l y (nearly half of this in the few morning hours). Aldosterone — 0.125 mg daily
  • These distortions of fluid and electrolyte balance progress and contribute to the circulatory collapse that occurs in adrenal insufficiency if excess salt is not ingested. It is this action which makes adrenal cortex essential for survival. The action of aldosterone is expressed by gene mediated increased transcription of m-RNA in renal tubular cells which directs synthesis of proteins (aldosterone-induced proteins—AIP).
  • Optimum level of cortisol is needed for normal muscular activity.
  • Irrespective of the type of injury or insult, the attending inflammatory response is suppressed by glucocorticoids. This is the basis of most of their clinical uses. The action is nonspecific and includes reduction of— increased capillary permeability, local exudation, cellular infiltration, phagocytic activity as well as late responses like capillary proliferation, collagen deposition, fibroblastic activity and ultimately scar formation. The action is direct and can be restricted to a site by local application. The cardinal signs of inflammation—redness, heat, swelling and pain are suppressed. Glucocorticoids interfere at several steps in the inflammatory response, but the most important overall mechanism appears to be limitation of recruitment of inflammatory cells at the local site. Production of PGs and several other mediators of inflammation like LTs, PAF, TNFα and cytokines is interfered by negative regulation of COX and other relevant enzymes. Glucocorticoids induce formation of anti-inflammatory protein called annexins which inhibits phospholipase A that is responsible for release of arachidonic acid from membrane phospholipids for PG and LT synthesis. Corticoids are only palliative, do not remove the cause of inflammation; the underlying disease continues to progress while manifestations are dampened. They favour spread of infections because capacity of defensive cells to kill microorganisms is impaired. They also interfere with healing and scar formation: peptic ulcer may perforate asymptomatically
  • s Glucocorticoids impair immunological competence. They suppress all types of hypersensitization and allergic phenomena. The clinical effect appears to be due to suppression of recruitment of leukocytes at the site of contact with the antigen, and of inflammatory response to immunological injury. They cause greater suppression of cell mediated immunity (CMI) in which T cells are primarily involved, e.g. delayed hypersensitivity and graft rejection. This is the basis of use in autoimmune diseases and organ transplantation. Factors involved may be inhibition of IL-1 release from macrophages; inhibition of IL-2 formation and action, so that T cell proliferation is not stimulated; suppression of natural killer cells, etc. Overall, corticosteroids interrupt cooperative cell-to-cell communication between immunological cells
  • which they are used are: 1. Collagen and autoimmune diseases, e.g. systemic lupus erythematosus, polyarteritis nodosa, nephrotic syndrome, glomerulonephritis, rheumatoid arthritis, rheumatic fever, acute gouty arthritis, haemolytic anaemia, thrombocytopenia, myasthenia gravis, etc. 2. Severe allergic reactions: anaphylaxis, angioneurotic edema, urticaria, serum sickness. 3. Bronchial asthma: majority of cases are treated with inhaled steroids. Other lung conditions benefited by corticosteroids are pulmonary edema, aspiration pneumonia, allergic rhinitis. Dexamethasone/betamethasone given to pregnant women before premature delivery, prevent respiratory distress syndrome in the neonate. 4. Eye diseases: allergic conjunctivitis, iridocyclitis, keratitis, uveitis, retinitis, optic neuritis, etc.

×